

# ONCOLOGY AGENTS



Included Products: Therapies on medical and pharmacy benefits

Created: 11/12/2020

Revised: 11/14/2024

Reviewed: 11/14/2024

Updated: 12/01/2024

*Italicized are nonformulary for outpatient benefit. PA required on medical benefit.*

Brand	Generic
Calquence	acalabrutinib
Krazati	adagrasib
Verzenio	ademaciclib
<i>Kadcyla</i>	<i>ado-trastuzumab</i>
Gilotrif	afatinib
Alecensa	alectinib
Piqray	alpelisib
<i>Rybrevant</i>	<i>amivantamab-vmjw</i>
<i>Erwinaze</i>	<i>asparaginase</i>
<i>Rylaze</i>	<i>asparaginase recombinant-rywn</i>
<i>Tecentriq</i>	<i>atezolizumab</i>
<i>Bavencio</i>	<i>avelumab</i>
Inlyta	axitinib
<i>Blenrep</i>	<i>belantamab mafodotin-blmf</i>
<i>Beleodaq</i>	<i>belinostat</i>
<i>Welireg</i>	<i>belzutifan</i>
<i>Bendeka</i>	<i>bendamustine</i>
<i>Treanda</i>	<i>bendamustine</i>
<i>Avastin</i>	<i>bevacizumab</i>

<b><i>Mvasi</i></b>	<i>bevacizumab-awwb</i>
<b><i>Zirabev</i></b>	<i>bevacizumab-bvzr</i>
<b><i>Alymsys</i></b>	<i>bevacizumab-maly</i>
<b>Mektovi</b>	binimetinib
<b><i>Blincyto</i></b>	<i>blinatumomab</i>
<b><i>Velcade</i></b>	<i>bortezomib</i>
<b>Bosulif</b>	bosutinib
<b><i>Adcetris</i></b>	<i>brentuximab</i>
<b>Alunbrig</b>	brigatinib
<b><i>Jevtana</i></b>	<i>cabazitaxel</i>
<b>Cabometyx</b>	cabozantinib
<b>Cometriq</b>	cabozantinib
<b><i>Asparlas</i></b>	<i>calaspargase pegol-mknl</i>
<b>Tabrecta</b>	capmatinib
<b><i>Kyprolis</i></b>	<i>carfilzomib</i>
<b><i>Libtayo</i></b>	<i>cemiplimab-rwlc</i>
<b>Zykadia</b>	ceritinib
<b><i>Erbitux</i></b>	<i>cetuximab</i>
<b>Cotellic</b>	cobimetinib
<b><i>Aliqopa</i></b>	<i>copanlisib</i>
<b>Xalkori</b>	crizotinib
<b>Tafinlar</b>	dabrafenib
<b>Vizimpro</b>	dacomitinib
<b><i>Darzalex</i></b>	<i>daratumumab</i>
<b><i>Darzalex Faspro</i></b>	<i>daratumumab-hyaluronidase-fihj</i>
<b>Sprycel</b>	dasatinib

<b>Vyxeos</b>	<i>daunorubicin/cytarabine</i>
<b>Dacogen</b>	<i>decitabine</i>
<b>Inqovi</b>	<i>decitabine/cedazuridine</i>
<b>Firmagon</b>	<i>degarelix</i>
<b>Unituxin</b>	<i>dinutuximab</i>
<b>Jemperli</b>	<i>dostarlimab</i>
<b>Doxil</b>	<i>doxorubicin liposomal</i>
<b>Imfinzi</b>	<i>durvalumab</i>
<b>Orserdu</b>	<i>elacestrant</i>
<b>Empliciti</b>	<i>elotuzumab</i>
<b>Elrexfo</b>	<i>elranatamab-bcmm</i>
<b>Idhifa</b>	<i>enasidenib</i>
<b>Braftovi</b>	<i>encoafenib</i>
<b>Padcev</b>	<i>enfortumab vedotin-ejfv</i>
<b>Rozlytrek</b>	<i>entrectinib</i>
<b>Epkinly</b>	<i>epcoritamab-bysp</i>
<b>Balversa</b>	<i>erdafitinib</i>
<b>Halaven</b>	<i>eribulin</i>
<b>Tarceva</b>	<i>erlotinib</i>
<b>Afinitor</b>	<i>everolimus</i>
<b>Enhertu</b>	<i>fam-trastuzumab deruxtecan-nxki</i>
<b>Fruzaqla</b>	<i>fruquintinib</i>
<b>Faslodex</b>	<i>fulvestrant</i>
<b>Lytgobi</b>	<i>futibatinib</i>
<b>Iressa</b>	<i>gefitinib</i>
<b>Infugem</b>	<i>gemcitabine</i>

<b><i>Mylotarg</i></b>	<i>gemtuzumab</i>
<b>Xospata</b>	gilteritinib
<b>Daurismo</b>	glasdegib
<b><i>Columvi</i></b>	<i>glofitamab-gxbm</i>
<b>Zydelig</b>	idelalisib
<b>Truseltiq</b>	infigratinib
<b><i>Besponsa</i></b>	<i>inotuzumab ozogamicin</i>
<b><i>Yervoy</i></b>	<i>ipilimumab</i>
<b><i>Onivyde</i></b>	<i>irinotecan lipo</i>
<b><i>Sarclisa</i></b>	<i>isatuximab-irfc</i>
<b>Tibsovo</b>	ivosidenib
<b><i>Ixempra</i></b>	<i>ixabepilone</i>
<b>Ninlaro</b>	ixazomib
<b>Tykerb</b>	lapatinib
<b>Vitrakvi</b>	larotrectinib
<b>Lazcluze</b>	Lazertinib
<b>Revlimid</b>	lenalidomide
<b>Lenvima</b>	lenvatinib
<b>Gleostine</b>	lomustine
<b>Lorbrena</b>	lorlatinib
<b><i>Margenza</i></b>	<i>margetuximab-cmkb</i>
<b><i>Alkeran IV</i></b>	<i>melphalan</i>
<b><i>Evomela</i></b>	<i>melphalan</i>
<b><i>Pepaxto</i></b>	<i>melphalan flufenamide</i>
<b><i>Elahere</i></b>	<i>mirvetuximab soravtansine-gynx</i>
<b>Exkivity</b>	mobocertinib

<b>Poteligeo</b>	<i>mogamulizumab-kpkc</i>
<b>Ojjaara</b>	momelotinib
<b>Lunsumio</b>	<i>mosunetuzumab-axgb</i>
<b>Lumoxiti</b>	<i>moxetumomab pasudotox-tdfk</i>
<b>Adstiladrin</b>	<i>nadofaragene firadenovec-vncg</i>
<b>Portrazza</b>	<i>necitumumab</i>
<b>Arranon</b>	<i>nelarabine</i>
<b>Nerlynx</b>	neratinib
<b>Tasigna</b>	nilotinib
<b>Zejula</b>	niraparib
<b>Akeega</b>	niraparib/abiraterone acetate
<b>Opdivo</b>	<i>nivolumab</i>
<b>Opdualag</b>	<i>nivolumab/relatlimab-rmbw</i>
<b>Gazyva</b>	<i>obinutuzumab</i>
<b>Arzerra</b>	<i>ofatumumab</i>
<b>Lynparza</b>	olaparib
<b>Lartruvo</b>	<i>olaratumab</i>
<b>Rezlidhia</b>	olutasidenib
<b>Synribo</b>	<i>omacetaxine mepesuccinate</i>
<b>Omisirge</b>	<i>omidubicel-onlv</i>
<b>Tagrisso</b>	osimertinib
<b>Abraxane</b>	<i>paclitaxel protein</i>
<b>Vonjo</b>	<i>pacritinib</i>
<b>Ibrance</b>	palbociclib
<b>Vectibix</b>	<i>panitumumab</i>
<b>Farydak</b>	panobinostat

<b>Votrient</b>	pazopanib
<b><i>Oncaspar</i></b>	<i>pegaspargase</i>
<b>Sylatron</b>	peginterferon
<b><i>Keytruda</i></b>	<i>pembrolizumab</i>
<b>Pemazyre</b>	pemigatinib
<b><i>Perjeta</i></b>	<i>pertuzumab</i>
<b><i>Phesgo</i></b>	<i>pertuzumab/trastuzumab/hyaluronidase-zzxf</i>
<b>Jaypirca</b>	pirtobrutinib
<b><i>Polivy</i></b>	<i>polatuzumab vedotin-piiq</i>
<b>Pomalyst</b>	pomalidomide
<b>Iclusig</b>	ponatinib
<b>Folotyn</b>	pralatrexate
<b>Gavreto</b>	pralsetinib
<b>Matulane</b>	procarbazine
<b>Vanflyta</b>	quizartinib
<b><i>Cyramza</i></b>	<i>ramucirumab</i>
<b>Stivarga</b>	regorafenib
<b><i>Zynyz</i></b>	<i>retifanlimab-dlwr</i>
<b>Kisqali</b>	ribociclib
<b>Qinlock</b>	ripretinib
<b><i>Rituxan Hycela</i></b>	<i>rituximab/hyaluronidase</i>
<b><i>Istodax</i></b>	<i>romidepsin</i>
<b>Rubraca</b>	rucaparib
<b><i>Trodelyv</i></b>	<i>sacituzumab govitecan-hziy</i>
<b>Xpovio</b>	selinexor
<b>Retevmo</b>	selpercatinib

<b>Sylvant</b>	siltuximab
<b>Provenge</b>	<i>sipuleucel-t</i>
<b>Fyarro</b>	<i>sirolimus protein-bound</i>
<b>Odomzo</b>	sonidegib
<b>Nexavar</b>	sorafenib
<b>Lumakras</b>	sotorasib
<b>Sutent</b>	sunitinib
<b>Monjuvi</b>	<i>tafasitamab</i>
<b>Elzonris</b>	<i>tagraxofusp</i>
<b>Talzenna</b>	talazoparib
<b>Imlygic</b>	<i>talimogene laherparepvec</i>
<b>Talvey</b>	<i>talquetamab-tgvs</i>
<b>Imdelltra</b>	<i>tarlatamab-dlle</i>
<b>Tazverik</b>	tazemostat
<b>Tecvayli</b>	<i>teclistamab-cqyv</i>
<b>Temodar IV</b>	temozolamide
<b>Torisel</b>	<i>temsirolimus</i>
<b>Tepmetko</b>	tepotinib
<b>Tabloid</b>	thioguanine
<b>Tivdak</b>	<i>tisotumab vedotin-tftv</i>
<b>Fotivda</b>	tivozanib
<b>Yondelis</b>	trabectedin
<b>Mekinist</b>	trametinib
<b>Herceptin</b>	<i>trastuzumab</i>
<b>Herzuma</b>	<i>trastuzumab-pkrb</i>
<b>Ontruzant</b>	<i>trastuzumab-dttb</i>

<b><i>Herceptin Hylecta</i></b>	<i>trastuzumab/hyaluronidase-oysk</i>
<b><i>Kanjinti</i></b>	<i>trastuzumab-aans</i>
<b><i>Ogivri</i></b>	<i>trastuzumab-dkst</i>
<b><i>Trazimera</i></b>	<i>trastuzumab-qyyp</i>
<b>Lonsurf</b>	trifluridine-tipiracil
<b>Tukysa</b>	tucatinib
<b>Ukoniq</b>	umbralisib
<b>Caprelsa</b>	vandetanib
<b>Zelboraf</b>	vemurafenib
<b>Venclexta</b>	venetoclax
<b><i>Marqibo</i></b>	<i>vincristine liposome</i>
<b>Erivedge</b>	vismodegib
<b>Zolinza</b>	vorinostat
<b>Brukina</b>	zanubrutinib
<b><i>Zaltrap</i></b>	<i>ziv-aflibercept</i>

<b>All Diagnoses</b>			
<b>Initial Criteria</b>		<b>If yes</b>	<b>If no</b>
<b>1.</b>	Is the treatment being prescribed or supervised by a hematologist or oncologist, as appropriate, for the type of cancer?	Continue to #2.	Do not approve.
<b>2.</b>	Is the treatment supported for the diagnosis in the NCCN guidelines?	Continue to #4.	Continue to #3.
<b>3.</b>	Is the treatment being used according to the FDA indication?	Continue to #4.	Request external specialty review.
<b>4.</b>	Does the request meet criteria for treatment coverage specified in Guideline Note 12 of the Prioritized List of Health Services, considering treatment of cancer with little or no benefit?	Continue to #5.	Do not approve.
<b>5.</b>	Approve for 12 months.		



Renewal Criteria		If yes	If no
1.	Has there been evidence of tumor response?	Continue to #2.	Do not approve.
2.	Approve for 12 months.		